Hyperkalemia is a diseases in which levels of potassium are higher than normal level (3.5 and 5.0 mmol/L) in blood serum. Kidneys are responsible for managing potassium balance in the body by regulating its excretion as well as its intake. A person is prone to develop hyperkalemia when the consumption of potassium exceeds that of kidneys’ potential to excrete it. The right amount of potassium and sodium in the body play a vital role in normal functioning of the myocardium.
Hyperkalemia can occur due to congestive heart failure, chronic kidney disease, or diabetic kidney disease. The condition can also occur when a patient receives renin-angiotensin-aldosterone system inhibitors (RAAS) in kidney disease. Abnormal levels of potassium can lead to irregular heartbeats, which can be fatal. Hyperkalemia is diagnosed by kidney functioning test, creatinine blood test, blood tests, and glucose monitoring.
In hospitalized patients, the incidence of hyperkalemia has ranged from 1% to 10%, depending on how the condition is defined.
The global Hyperkalemia Treatment market is valued at US$ 434.37 million in 2020. The market size will reach US$ 1682.53 million by the end of 2027, growing at a CAGR of 20.86% during 2021-2027. In 2020 the global Hyperkalemia Treatment sales volume is 41294 thousand units and it will be 170313 thousand units in 2027, with a CAGR of 22.48% between 2021 and 2027.
Global Hyperkalemia Treatment Market- Key Players
Vifor Pharma, Astrazeneca, Sanofi, CMP Pharma, Belcher Pharmaceuticals, etc. are the leaders of the industry, with high-end customers. The top five manufacturers held 57.83% of the market, in terms of Hyperkalemia Treatment revenue in 2020. Besides the top 5 players, there are also many small and medium sized companies who are dedicated to developing hyperkalemia drugs.
Global Hyperkalemia Treatment Market: Segmental Analysis
The classification of Hyperkalemia Treatment includes Patiromer, Sodium Zirconium Cyclosilicate, etc. Patiromer is used to treat hyperkalemia (high levels of potassium in the blood). Patiromer is in a class of medications called potassium removing agents. Sodium zirconium cyclosilicate is a non-absorbed cation-exchange compound that acts as a selective potassium binder in the gastro-intestinal tract. In 2020, Patiromer accounted for a share of 29.96% in the global Hyperkalemia Treatment market. In addition, this product segment is poised to reach US$ 399.43 million by 2027 from US$ 117.79 million in 2021.
Read More Information: https://www.qyresearch.com/index/detail/3251339/global-hyperkalemia-treatment-market
QYResearch provides Market Research Reports for clients all over the world. As of now, QYResearch data as following:
62000 + Clients(cover 100% the world strong 500 companies and most industries’ leading players such as TOP5 players)
7800 + Experts(most of them with more than 15 years’ experience in their industry and professional knowledge both in market and technology)
300 + Data Base(40% government related data base, 30% third part data base, 10% international agencies data base, 30% technology and market data base)
2 Million + Reports(cover almost all industries and most detailed products such as product model level research reports, where you can find all what you need in one shop)
1000 + Custom Research Projects(most clients need custom research service and QYResearch keeps offering good and depth service for them)
30 + Roles Data Interview Checking System(only QYResearch uses such interview system with more than 30 roles in order to confirm the data reliability)
13 + Years focus market research and continues to support the client success.
Rahul Singh - Digital Marketing Director
Contact: +91 7028 920 828 +81-903-800-9273 +86-108-294-5717
Sales Contact US:
USA Registered Office: QY Research, INC.
17890 Castleton, Suite 369,
City of industry, CA - 91748
Emails – firstname.lastname@example.org
Web – www.qyresearch.com